Skip to main content

Table 1 Baseline characteristics of study participants

From: Synergistic effect of chronic kidney disease, neuropathy, and retinopathy on all-cause mortality in type 1 and type 2 diabetes: a 21-year longitudinal study

Characteristics

 

N

303

Age, years—median [IQR]

58 [19]

Women—no. (%)

155 (51.2)

Body weight, kg—median [IQR]

77 [19]

Body mass index, kg/m2—median [IQR]

27.7 [7.5]

Systolic blood pressure, mmHg—median [IQR]

140 [29]

Diastolic blood pressure, mmHg—median [IQR]

78 [11]

Diabetes mellitus—no. (%)

 

  Type 2 Diabetes—no. (%)

218 (71.9)

  Type 1 Diabetes—no. (%)

85 (28.1)

Duration of diabetes—median [IQR]

11 [16]

Smoke—no. (%)

95 (31.4)

Hypertension—no. (%)

168 (55.4)

Fasting glucose, mg/dl—median [IQR]

166 [92]

HbA1c, %—median [IQR]

8.8 [2.7]

Total cholesterol, mg/dl—median [IQR]

211 [68]

HDL cholesterol, mg/dl—median [IQR]

45 [16]

LDL cholesterol, mg/dl—median [IQR]

132 [56]

Triglycerides, mg/dl—median [IQR]

142 [102]

Creatinine, mg/dl—median [IQR]

0.87 [0.26]

mGFR, ml/min/1.73 m2—median [IQR]

99.5 [37.3]

eGFR, ml/min/1.73 m2—median [IQR]

84.4 [26.3]

Albuminuria, μg/min—median [IQR]

7.6 [14.6]

Glucose-lowering therapy—no. (%)

255 (84.2)

  Oral agents—no. (%)

117 (38.6)

    Biguanides—no. (%)

128 (42.2)

    Sulphonylureas—no. (%)

85 (28.1)

    Acarbose—no. (%)

9 (3.0)

  Insulin—no. (%)

152 (50.2)

  Insulin, UI/die—median [IQR]

40 [18]

Lipid-lowering therapy—no. (%)

26 (8.6)

Anti-hypertensive therapy—no. (%)

168 (55.5)

  ACEi/ARB—no. (%)

121 (39.9)

  Beta-Blockers—no. (%)

18 (5.9)

  Ca-Blockers—no. (%)

68 (22.4)

  Alpha-Blockers—no. (%)

33 (10.9)

  1. ACEi angiotensin converting enzyme inhibitors, ARB angiotensin II receptors blockers, eGFR estimated glomerular filtration rate, HDL high-density lipoprotein, IQR interquartile range, LDL low-density lipoprotein, mGFR measured glomerular filtration rate